Research Study

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
Principal Investigator 
Kevin Song

Overview

Disorders and Conditions 
Amyloidosis
ClinicalTrials.gov# 
NCT03201965
Status 
Recruiting
Study Start/End 
Sep 14, 2018 to Jan 31, 2024
Locations 
Vancouver General Hospital
Name/Title 
Larissa Pals, Research Assistant
Phone 
604-875-4111 ext.22967
Purpose of Study 

The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.